Josh Shin

Practice Areas

MR. JOSH SHIN SPECIALIZES IN CORPORATE AND COMMERCIAL LAW MATTERS. HE HAS MAINTAINED A BALANCED PRACTICE STYLE BETWEEN TRANSACTION AND REGULATORY MATTERS, WITH A CONVINCING TRACK RECORD IN VARIOUS INDUSTRY SECTORS SUCH AS PHARMA, LIFE SCIENCE, PRIVATE EDUCATION AND GENERAL INDUSTRIES SECTORS.

Publications

Lead Author “Pharma Legal Handbook – PRC” published by Pharma Boardroom (edition 2019 and 2021).

Personal

Honors and Awards

Recommended as ranked lawyer for healthcare by Chambers and Partners – Asia Pacific 2019 – 2022

Recommended as leading individual for “healthcare and life-science” by Legal 500 –Asia Pacific 2020 – 2022

Pharmaceutical, Medical and Biotech M&A Legal Advisor of the Year 2019, by Merger Market

Experience

M&A/Corporate Transactions:

-Representing AnHeart Therapeutics on its full acquisition by Nuvation Bio, a US biopharmaceutical company listed on NYSE (NYSE: NUVB), in an all-stock transaction.

-Representing AnHeart Therapeutics in its cross-border restructuring and Series A+/A-2/B/C equity financing.

-Representing E-Shang Redwood in its series acquisitions/disposals of 30+ logistic assets in China.

-Representing AstraZeneca in its investment of new manufacturing facilities in Qingdao, Taizhou and Wuxi for a total value of RMB10billion.

-Representing Redwood China Logistics Fund and other sellers in the sale of top tier logistics assets in PRC mainland to the entity established by ESR and Manulife Financial Group.

-Representing multiple life sciences start-ups, such as Cascade, EddingPharm and MitrAssist, in their various rounds of equity financing.

-[Ongoing]Representing AstraZeneca global in its participation in Series A equity financing of a China biotech company.

-Representing Eddingpharm on its acquisition from Eli Lilly of the rights for two legacy antibiotic medicines in China: Ceclor and Vancocin, as well as a manufacturing facility in Suzhou.

-Representing Bayer Healthcare China in selling its TCM products and manufacturing plant to a leading China pharmaceutical company.

-Representing Education Index Management (the owner of Dulwich College International) in its various rounds private equity financing and restructuring of its China businss.

Representing Everbright Holdings in its investment in Shenzhen Lifetech (01302.HK), the leading supplier of minimally invasive interventional medical devices to treat cardiovascular diseases.

-Representing Covestro AG in its proposed acquisition of a leading thin film company in Guangdong Province.

-Representing Ping’An, ARA, LOGOS, and Sun Jade Capital in its series acquisitions of logistic assets in China.

-Representing Bayer HealthCare China in reorganization its corporate structure for integration with the onshore part of Merck OTC Business, following Bayer’s global acquisition of Merck OTC department.

-Representing Bayer AG in its acquisition of 100% interest in Dihon Pharmaceutical Group, a leading OTC and traditional Chinese medicine company in China.

-Representing Wuxi AppTec in forming a joint venture with Mayo Clinics regarding advanced medical examination technologies.

-Advising British Education (running Wycombe Abby China schools) in its private equity financing as well as operational matters.

-Representing World Strides, the largest educational travel company in the world, in acquiring summer camping business in China.

-Representing Parkway Health, a leading healthcare services provider in Asia in its investment into several private hospitals and clinics in various provinces in China.

Product License/Collaboration:

-Represented AstraZeneca in multiple combo study projects with certain biopharma companies including Ascentage Pharma, Wuxi BioCity, Shanghai JMT and Genhouse.

-Representing Kanghua in granting HilleVax the exclusive rights to develop, manufacture and commercialize Kanghua’s hexavalent virus-like particle (VLP) vaccine candidate for norovirus in the ex-Greater China territory.

-Represented Hengrui Pharmaceuticals in its out-licensing partnership with Aiolos Bio with respect to Hengrui’s innovative anti-TSLP monoclonal antibody (SHR-1905) in ex-Greater China territory.

-Represented CStone Pharmaceuticals in out-licensing of exclusive development, registration, manufacturing and commercialization right related to anti-PD-1 monoclonal antibody (nofazinlimab) in mainland China to 3SBio Inc.

-Representing multiple MNCs in exclusive promotion and/or CSO arrangements with respect to their core products with partners in China market.

-Representing AstraZeneca in reaching a co-promotion arrangement with Daiichi Sankyo of DS8201 in China market following a global license of DS8201.

-Representing CStone Pharmaceuticals in granting the exclusive rights to Hengrui Pharmaceuticals for research, development, registration, manufacturing, and commercialization of anti-CTLA-4 mAb CS1002 in the Greater China region.

-Representing medical devices companies including Baxter and Cordis, in connection with its contract design, contract R&D and contract manufacturing transaction in China market.

-Representing OnCusp Therapeutics in obtaining global (ex-China) exclusive license to an ADC drug candidate from Multitude Therapeutics.

-Representing Anheart Therapeutics, in granting exclusive commercialization right in PRC market with respect to Anheart’s lead drug candidate taletrectinib, a next-generation tyrosine kinase in¬hibitor (TKI) designed to effectively target ROS1 and NTRK to Innovent, in China Market and to Nippon Kayaku, a listed company in Japan, in Japan market respectively.

-Representing Tibet Rhodiola (known as Tibet Pharmaceuticals) in obtaining certain rights with respect to Sputnik-V, an adenovirus vector-based COVID-19 vaccine from Russia Direct Investment Fund (belongs to Russia Sovereign).

-Representing AstraZeneca in granting to BioKangtai the exclusive license in China with respect to the AZD1222, an adenovirus vector-based COVID-19 vaccine initially developed by Oxford University.

-Representing C-Stone Pharmaceuticals in its obtaining of global license from WuXi Biologics relating to PD-L1/TGFβ bifunctional molecule.

-Representing AstraZeneca in obtaining the exclusive promotion rights Luye Pharmaceuticals with respect to Xue Zhi Kang Capsule, a first-line blood lipid management drug. This is the first time that a multinational pharmaceutical company has gained exclusive authorization in China to promote an innovative drug independently developed by a Chinese pharmaceutical company.

-Representing AstraZeneca in its granting of certain rights in China relating to a key originator drug to a leading domestic pharma company.

-Representing Novartis in its granting of exclusive promotion rights in China in relation to certain respiratory drugs to a leading domestic pharma company.

-Representing AstraZeneca in its granting of exclusive commercialization rights to Plendil in China market to China Medical System for an upfront fee of USD310million and ongoing economic sharing.

-Representing AstraZeneca in its granting of exclusive commercialization rights to certain GLP-1 diabetes drugs in China market to 3Sbio for an upfront fee of USD100million and ongoing economic sharing.

General Corporate/Regulatory Works:

-Advising life sciences companies in responding to NMPA investigations.

-Representing Johnson Matthey, Covestro AG, E-Shang Redwood, Education Index, Celanese and a number of other companies, in regulatory issues arising from daily business.

-Representing life sciences companies including AstraZeneca, BMS, Brii, AnHeart Therapeutics, Pfizer, Organon, Smith Nephew, Novartis AG, Boehringer Ingelheim, Roche Pharmaceuticals, C-Stone Pharmaceuticals, MediLink Therapeutics, Zai Lab, Biogen, Laekna Therapeutics, Bayer Healthcare, and Karl Zeisss, in regulatory issues arising from daily business, including research and development projects, clinical trials, market authorization, product distribution, PAP/PSP, PBM, product promotion, and NGO/PAG interactions, and acting as de facto GC for some of start-up businesses.

-Advising Dulwich College International China schools, Dehong Chinese International School, Shanghai Concord Bilingual School and Nord Anglia schools on various legal issues in daily operation, including new school opening, campus construction/expansion, regulatory compliance, related party transaction, procurement, data protection, school management, debt financing, etc.

-Advising partners of Alibaba in establishing Yungu School.

Capital Markets:

-Advising issuers/underwriters in a number of initial public offerings and other capital market transactions, including IPO of EddingPharm at HKSE (A-1 submission), follow-on offering of Chi-Med at NASDAQ, IPO of C-Stone Pharmaceuticals at HKSE, IPO of Zai Lab at NASDAQ, IPO of Wuxi Biologics at HKSE, IPO of Simcom at HKSE, IPO of Ruici Health at HKSE, IPO and follow-up offerings of Trina Solar at NASDAQ, IPO of Montage Technology at NASDAQ, IPO of ShangPharma at NYSE, IPO of China iKang at NYSE, etc.

-Representing the buyers group led by the founder and TPG in its taking private of ShangPharma Corporation, a leading China-based CRO company.

-Representing the buyers group led by the founder in its attempted taking private of iKang Healthcare Group Inc.

Career

Josh has been dedicated to public welfare and the professional growth of young professionals for many years, and is an active contributor and council member of NGLegal, a youth legal development program.

Education